Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, Moshe Mittelman, MD, Amy Zhou, MD, Hetty E. Carraway, MD MBA, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Robert Leong, Peony Yu, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142499

Published: 2020

Journal Articles

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Moshe Mittelman, MD, Amy Zhou, MD, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Leong Robert, Kin-Hung P Yu, MD

Blood (2019) 134 (Supplement_1): 843.

https://doi.org/10.1182/blood-2019-128714

Published: 2019

Journal Articles

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Amy Zhou, MD, Stephen T. Oh, MD

Blood (2019) 134 (Supplement_1): 4210.

https://doi.org/10.1182/blood-2019-131128

Published: 2019

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

Amy Zhou, MD, Maggie J. Allen, Mary Fulbright, Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2018-99-113661

Published: 2018

Journal Articles

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Elizabeth K. Engle, PhD, Olga Malkova, PhD, Mary C. Fulbright, Amy Zhou, MD, Stephen Oh, MDPhD

Blood (2015) 126 (23): 602.

https://doi.org/10.1182/blood.V126.23.602.602

Published: 2015

Journal Articles

Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients

Rohit Kumar, Rohtesh S. Mehta, MD, MPH, MS, Amy Zhou, MD, Roy E. Smith, MD

Blood (2013) 122 (21): 2311.

https://doi.org/10.1182/blood.V122.21.2311.2311

Published: 2013

NARROW

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients

Email alerts

ASH Publications

American Society of Hematology

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only